Baltimore Sun -- Biopharmaceutical company Shire plans to close its Owings Mills plant in phases over three years and lay off 260 workers as it discontinues in-house manufacturing of drugs to treat attention-deficit and hyperactivity disorders and gastrointestinal diseases, a company spokesman said Thursday.
